MASTER DAPT
Research type
Research Study
Full title
MAnagement of high bleeding risk patients post bioresorbable polymer coated STEnt implantation with an abbReviated versus prolonged DAPT regimen – MASTER DAPT
IRAS ID
221119
Contact name
David Hildick-Smith
Contact email
Sponsor organisation
European Cardiovascular Research Institute (ECRI)
Duration of Study in the UK
3 years, 2 months, 0 days
Research summary
Both the European and American Cardiologist’s guidelines acknowledge that currently, there is limited information available about short and long term use of DAPT in patients who, on average are more likely suffer from complications such as bleeding on prolonged DAPT.
The purpose of this study is to add evidence to these guidelines and standardise our practice in treating patients who are at high risk of bleeding (HRB). To do this we need to compare a shorter versus longer length of DAPT.
MASTER DAPT is an investigator-initiated, multi-center and randomised study. It predicts the inclusion of a total of 4300 patients by 100 different study sites distributed throughout the world. Each patient is expected to participate in the study for 14 months after randomisation.REC name
London - Brighton & Sussex Research Ethics Committee
REC reference
17/LO/0108
Date of REC Opinion
30 Mar 2017
REC opinion
Further Information Favourable Opinion